

奏効率：人種別 X 喫煙歴別

	非喫煙者	喫煙者	全体
東洋人	イレッサ 17.6% (15/85) プラセボ 0% (0/40)	イレッサ 8.9% (11/124) プラセボ 3.5% (2/57)	イレッサ 12.4% (26/209) プラセボ 2.1% (2/97)
東洋人以外	イレッサ 18.5% (22/119) プラセボ 0% (0/66)	イレッサ 4.6% (29/631) プラセボ 1.3% (4/317)	イレッサ 6.8% (51/750) プラセボ 1.0% (4/383)
全体	イレッサ 18.1% (37/204) プラセボ 0% (0/106)	イレッサ 5.3% (40/755) プラセボ 1.6% (6/374)	

バリデーションによって奏効率の評価可能症例数、奏効例等の数字が変更(下線部の数値が1月20日発表分(プラセボ群は提示せず)から変更)

直近の化学療法に忍容でなかった患者群の患者背景に関する資料

demography for intolerant patients



	Gefitinib N=114	Placebo N=48
Age (median)	64 years	65 years
Age < 65 years	52%	50%
Age >= 65 years	48%	50%
Male	61%	58%
PS 0-1	82%	83%
Never smoked	23%	21%
Oriental	14%	6%
Refractory	0%	0%
Intolerant	100%	100%
Histology	Adenocarcinoma	38%
Time from diagnosis to randomisation	< 6 months	17%
	6-12 months	23%
Best response to prior chemotherapy	CR/PR	54%
	SD	40%
	PD/NE	6%

東洋人/非東洋人・喫煙者/非喫煙者別の
サブグループにおける調整因子毎の生存期間に関する資料

Oriental

Survival according to histology

— Gefitinib - - - - - Placebo





Survival time (months)

Oriental

Survival by smoking history

— Gefitinib - - - - - Placebo




Survival time (months)

Oriental

Survival by reason for stopping prior chemotherapy

— Gefitinib - - - - Placebo





. = too few events (<20) for a meaningful analysis (central limit theorem breakdown)

Oriental

Survival by line of therapy



— Gefitinib - - - - Placebo



Oriental

Survival by performance status

— Gefitinib - - - - Placebo





Survival time (months)

Oriental


Survival by gender

— Gefitinib - - - - - Placebo



Oriental Non-smoker

Survival according to histology




. = too few events (<20) for a meaningful analysis (central limit theorem breakdown)

Oriental Non-smoker

Survival by reason for stopping prior chemotherapy


— Gefitinib - - - - - Placebo



. = too few events (<20) for a meaningful analysis (central limit theorem breakdown)

Oriental Non-smoker


Survival by line of therapy



Oriental Non-smoker

Survival by performance status


— Gefitinib - - - - - Placebo



Oriental Non-smoker

Survival by gender

— Gefitinib - - - - Placebo



. = too few events (<20) for a meaningful analysis (central limit theorem breakdown)

Non-Smoker

Survival according to histology

— Gefitinib - - - - Placebo

Adenocarcinoma

HR 0.65, p=.034 (SLR)
HR 0.61, p=.009 (Cox)
HR 0.64, p=.014 (LR)

Non Adenocarcinoma

HR 0.99, p=.968 (SLR)
HR 0.99, p=.964 (Cox)
HR 0.93, p=.789 (LR)

